<DOC>
	<DOCNO>NCT01185288</DOCNO>
	<brief_summary>This study investigate efficacy low high dos methotrexate ( MTX ) combination open-label adalimumab ( ADA ) patient inadequate response high dose MTX . The study also evaluate pharmacokinetics safety two regimen MTX combination ADA participant rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>A Study Determine Effect Methotrexate ( MTX ) Dose Clinical Outcome Ultrasonographic Signs Subjects With Moderately Severely Active Rheumatoid Arthritis ( RA ) Treated With Adalimumab ( MUSICA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Adult subject moderately severely active rheumatoid arthritis Subjects must DAS28 ( CRP ) ( Disease Activity Score use CReactive Protein ) great equal 3.2 baseline ( minimum CRP score require qualify ) Subjects must least 5/68 tender joint plus 5/66 swollen joint assess screen baseline Subject must treat MTX ( methotrexate ) dose ( oral and/or injectable ) 15 mg per week ( upper limit dose ) least 12 week prior screen Subject either biologicna√Øve one prior biologic diseasemodifying antirheumatic drug ( i.e . abatacept , anakinra , certolizumab , etanercept , golimumab , infliximab , tocilizumab ) Previous exposure adalimumab ( Humira ) , rituximab ( Rituxan ) , natalizumab ( Tysabri ) , efalizumab ( Raptiva ) Subject treat intraarticular parenteral administration corticosteroid within 4 week screen Subject diagnosis history gout pseudogout Subject undergone joint surgery within 12 week screen ( joint assess ultrasound ) Subject history chronic arthritis diagnose age 16 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>